Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
Who is this study for? Patients with Alzheimer's disease
What treatments are being studied? Glycine+N-acetylcysteine
Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the effects of supplementing glycine and N-acetylcysteine vs. alanine as placebo on these defects in AD, and examine the effects on cognition.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 55
Maximum Age: 85
Healthy Volunteers: f
View:
• Age 55-85 years;
• Gradual and progressive memory loss for more than 1 year, with a Montreal Cognitive Assessment score of 10-20;
• Amyloid positivity on PET scan;
• Availability of a study partner.
Locations
United States
Texas
Baylor College of Medicine
RECRUITING
Houston
Contact Information
Primary
Rajagopal V Sekhar, M.D.
rsekhar@bcm.edu
7137983908
Time Frame
Start Date: 2022-02-15
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 52
Treatments
Experimental: Glycine plus N-acetylcysteine
Glycine and cysteine are amino-acid (protein) precursors of glutathione. Cysteine is provided as N-acetylcysteine
Placebo_comparator: Alanine
Alanine is an amino-acid (protein), and not a precursor of glutathione synthesis
Related Therapeutic Areas
Sponsors
Leads: Baylor College of Medicine
Collaborators: The Methodist Hospital Research Institute